Status:
TERMINATED
Resveratrol in Type2 Diabetes and Obesity
Lead Sponsor:
University at Buffalo
Collaborating Sponsors:
Kaleida Health
Conditions:
Type 2 Diabetes
Obesity
Eligibility:
All Genders
20+ years
Phase:
NA
Brief Summary
The main objective of this study is to investigate the effect of resveratrol (plant derived food supplement) on inflammatory mediators and insulin resistance at the cellular and molecular level in obe...
Detailed Description
The main objective of this study is to investigate the effect of resveratrol on inflammatory mediators and insulin resistance at the cellular and molecular level in obese non diabetic and type 2 diabe...
Eligibility Criteria
Inclusion
- 20 years of age and older
- Healthy Obese subjects with BMI \> 30
- Type 2 Diabetics with BMI \> 30
- Subjects with good peripheral vein.
- Subjects on statins, ACE inhibitors and thiazolidenediones will be allowed as long as they are on stable doses of these compounds and the dosage is not changed during the course of study.
Exclusion
- Subjects on any antioxidant medication
- Patient on non-steroidal anti-inflammatory drug
- On any agent with significant antioxidant properties.
- History of drug or alcohol abuse
- Any life threatening disease
- Allergy to peanuts, grapes, wine, mulberries.
- Pregnant women.
- Coronary event or procedure (myocardial infarction, unstable angina, coronary artery bypass surgery or coronary angioplasty) in the previous four weeks.
- Subjects on anticoagulants.
Key Trial Info
Start Date :
December 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 8 2012
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT01158417
Start Date
December 1 2008
End Date
July 8 2012
Last Update
November 9 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Jeanne Hejna
Williamsville, New York, United States, 14221